Systemic Inflammation is Associated with Cardiometabolic Risk Factors and Clinical Outcomes
Brandon Tejada,Roby Joehanes,Shih-Jen Hwang,Tianxiao Huan,Chen Yao,Jennifer E Ho,Daniel Levy
DOI: https://doi.org/10.2147/JIR.S382620
IF: 4.5
2022-12-29
Journal of Inflammation Research
Abstract:Brandon Tejada, 1, 2 Roby Joehanes, 1, 2 Shih-Jen Hwang, 1, 2 Tianxiao Huan, 1– 3 Chen Yao, 1, 2 Jennifer E Ho, 4 Daniel Levy 1, 2, 5 1 Framingham Heart Study, Framingham, MA, USA; 2 Population Sciences Branch, National Heart, Lung, and Blood Institute, Bethesda, MD, USA; 3 Ophthalmology and Visual Sciences, University of Massachusetts Medical School, Worcester, MA, USA; 4 CardioVascular Institute and Division of Cardiology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, Unites States; 5 Boston University School of Medicine, Boston, MA, USA Correspondence: Daniel Levy, Framingham Heart Study, 73 Mt. Wayte Avenue, Suite 2, Framingham, MA, 01702, USA, Email Purpose: Assessing an individual's systemic inflammatory state is vital to understand inflammation's role in cardiometabolic diseases and identify those at the greatest risk of disease. We generated global inflammation scores and investigated their associations with cardiometabolic risk factors and adverse outcomes. Patients and Methods: Aggregate Inflammation Scores (AIS) and Principal Component Analysis (PCA) scores were generated for 7287 Framingham Heart Study participants using up to 26 inflammation-related proteins, with higher scores reflecting a pro-inflammatory milieu. Multivariable regression and proportional hazards analyses were conducted to investigate the associations of inflammation with cardiometabolic risk factors and outcomes. The primary outcomes for cross-sectional analyses included age, cigarette smoking, fasting lipid and glucose levels, blood pressure, body mass index (BMI), and hypertension, diabetes, and obesity. For prospective analyses, new-onset hypertension, diabetes, obesity, cardiovascular disease and all-cause mortality were investigated. Results: Higher inflammation scores were associated with smoking and older age, higher BMI, systolic blood pressure, lipids, and glucose levels, and with greater odds of hypertension and diabetes after adjusting for age, sex, cohort, and BMI (all p < 0.001). Higher baseline scores were associated with greater odds of new-onset hypertension after adjusting for traditional risk factors (OR [95% CI] per one standard deviation [1-SD] increase, AIS: 1.33 [1.21– 1.47], PCA score: 1.26 [1.12– 1.42], p < 0.001). The AIS also was associated with new-onset diabetes (1.32 [1.14– 1.52], p < 0.001). Proportional hazards analyses revealed greater risk of new-onset cardiovascular disease events and all-cause mortality (HR [95% CI] per 1-SD, AIS: 1.25 [1.14– 1.37] and 1.32 [1.23– 1.42], PCA score: 1.22 [1.13– 1.33] and 1.40 [1.31– 1.49], p < 0.001). Conclusion: Global inflammation scores encompassing an array of pro- and anti-inflammatory proteins and pathways may enhance risk assessment for cardiometabolic diseases. The AIS and PCA scores provide further opportunities to investigate the mechanisms of inflammation-related risk of disease. Keywords: inflammation scores, cardiovascular disease, heart failure, pathways Inflammation pathways play a critical role in health and disease. Through acute inflammatory processes including vasoconstriction, leukocyte chemotaxis and extravasation, and the acute phase response, the innate immune system, and to some extent the adaptive immune system, protects the body against foreign pathogens, tissue damage, and oxidative stress. Excessive and protracted inflammation, however, can culminate in chronic inflammation that is a feature of atherosclerosis, a key contributor to cardiovascular disease (CVD). 1–3 In addition to its role in CVD, chronic inflammation is a critical contributor to kidney, 4–6 lung, 7 and autoimmune diseases. 8 It is thought that the association of inflammation with CVD is mediated in part by dysregulated inflammation. The ability to better assess the inflammatory milieu may thus aid in understanding an individual's risk of CVD and other inflammation-linked diseases. Previous studies have explored the adverse consequences of excessive inflammation and its relations to long-term health and predisposition to disease. 9 Associations of protein biomarkers of systemic and acute inflammation with risk of myocardial infarction, type 2 diabetes, and chronic obstructive pulmonary disease have been reported in both cross-sectional and prospective studies. 10–12 More recently, several studies have generated multi-marker inflammation scores to explore how systemic inflammation is linked to a variety of adverse clinical outcomes. Many of these studies relied on circulating levels of a small number of pr -Abstract Truncated-
immunology